bioRxivGeneticsPreprint
Cell autonomous inflammation in VEXAS is mediated by cGAS-STING
Samuel J. MagazineriD, Jason C. CollinsiD, Brecca MilleriD, Patrick Zheng, Amy K. WangiD, Jérôme HadjadjiD, Juan Carlos BalandrániD, Maria SirenkoiD, Maya EnglishiD, James Bertlin, Rebecca L. MurrayiD, Peter H. WhitneyiD, Tania J González-RoblesiD, Deborah Rivera, Yan WangiD, Duy T. TraniD, Zulfeqhar Ali SyediD, Valentina BaenaiD, Timothée LionnetiD, Kelly V. RugglesiD, Iannis AifantisiD, Dan Avi LandauiD, Achim A WerneriD, David B. BeckiD
Abstract
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a severe adult-onset inflammatory disease caused by somatic mutations that reduce cytoplasmic activity of UBA1, the primary initiating enzyme for ubiquitylation. How this hypomorphic state drives cell-intrinsic immune activation in mature myeloid cells is unknown. Using unbiased multi-omic, biochemical, and cell biological analyses of model systems and patient-derived cells, we show that loss of cytoplasmic UBA1 activity convergently disrupts endoplasmic reticulum- associated degradation (ERAD) and mitochondrial homeostasis. ERAD failure arises from preferential under-charging of ERAD E2 enzymes, explaining hallmark VEXAS features, including ER-derived vacuoles and unfolded protein response activation, and promotes accumulation of the ERAD substrate STING. Simultaneously, mitochondrial dysfunction drives cytosolic leakage of mitochondrial DNA, inducing cGAS-dependent STING signaling and inflammatory cytokine production. STING inhibition or reversal of mitochondrial DNA leakage resolves multi-cytokine inflammation in VEXAS models and patient myeloid cells, establishing the cGAS-STING pathway as a therapeutically actionable vulnerability.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Characterization of a maintainable human myeloid model of VEXAS syndrome with enhanced TNF-induced cell death and DAMP release
Yuma Sakamoto, Nobuyasu Baba, … Tomoyuki Mukai·bioRxiv·Sep 14, 2026
- UBA1 Mutations Drive RIPK1-Mediated Cell Death and Monocyte Dysfunction in VEXAS Syndrome
Paul Breillat, Samuel J. Magaziner, … Benjamin Terrier·bioRxiv·Oct 6, 2025
- Disturbing immune homeostasis by neutrophil loss of Uba1 induces VEXAS-like autoinflammatory disease in mice
Ge Dong, Jingjing Liu, … Zhigang Cai·Journal of Clinical InvestigationPeer-reviewed·Sep 4, 2025
- Single-cell genotype-phenotype mapping identifies therapeutic vulnerabilities in VEXAS syndrome
Saravanan Ganesan, Rebecca M. Murray, … Dan Avi Landau·bioRxiv·May 19, 2024
- Primary CD34+ cells of patients with VEXAS syndrome are highly sensitive to targeted treatment with TAK-243 and pevonedistat
Daniel Nowak, Marie Demmerle, … Nanni Schmitt·bioRxiv·May 22, 2025
- A conserved ion channel function of STING mediates non-canonical autophagy and cell death